PDF(Pubmed)
Abstract：
UNASSIGNED: Prefilled syringes (PFS) and various types of pens are available for subcutaneous injection of methotrexate (MTX) in patients with rheumatoid arthritis or moderate to severe psoriasis. A new MTX pen with modernized button-free autoinjection technology was developed as a successor to a button-activated pen (metoject®/metex® PEN). To assess the needs of users and the relevance of features of the new MTX autoinjector an international online survey was performed.
UNASSIGNED: A structured questionnaire was distributed to physicians, nurses and patients in Germany, France, and the United Kingdom. Participants received illustrations and information about features of the new MTX autoinjector.
UNASSIGNED: In total, 189 rheumatologists, 111 dermatologists, 90 nurses, and 180 patients answered the questions. Specific reasons for a preference for the use of MTX pens over PFS could predominantly be assigned to the categories \"dosing/administration\" and \"ease of use\". The first impression of the new MTX autoinjector was positive in 82% of physicians, 87% of nurses, and 76% of patients, respectively. The four most important features of the new MTX autoinjector were 2-step autoinjector mechanism (receiving a mean 14.1 to 18.1 chips of a total of 100 chips), small injection volume (9.7 to 11.7 chips), 10 different doses for dose flexibility (8.0 to 13.2 chips), and short injection time below 5 seconds (8.5 to 11.1 chips).
UNASSIGNED: Arguments for the use of MTX pens as opposed to PFS predominantly refer to dosing/administration and ease of use. The new button-free MTX autoinjector combines a number of advantageous features identified by the international survey.
Subcutaneous injection of methotrexate (MTX) is an option to treat patients with specific inflammatory diseases. A new MTX autoinjector with button-free activation of the injection and no need to build a skin fold was developed to address some of the reasons for non-adherence. The importance of specific needs of users as well as the relevance of features of the new MTX autoinjector are unknown. Therefore, a structured questionnaire was distributed to physicians, nurses and patients in Germany, France, and the United Kingdom. Illustrations and information about features of the new MTX autoinjector were distributed to the participants. The results of the study show that arguments for the use of MTX pens as opposed to prefilled syringes predominantly affect the categories dosing/administration and ease of use followed by safety/side effects. In addition, the study identified four main advantageous features of the new MTX autoinjector, ie simplicity due to the 2-step button-free autoinjector mechanism, the small injection volume, 10 different doses for dose flexibility, and the short injection time below 5 seconds.
UNASSIGNED: A structured questionnaire was distributed to physicians, nurses and patients in Germany, France, and the United Kingdom. Participants received illustrations and information about features of the new MTX autoinjector.
UNASSIGNED: In total, 189 rheumatologists, 111 dermatologists, 90 nurses, and 180 patients answered the questions. Specific reasons for a preference for the use of MTX pens over PFS could predominantly be assigned to the categories \"dosing/administration\" and \"ease of use\". The first impression of the new MTX autoinjector was positive in 82% of physicians, 87% of nurses, and 76% of patients, respectively. The four most important features of the new MTX autoinjector were 2-step autoinjector mechanism (receiving a mean 14.1 to 18.1 chips of a total of 100 chips), small injection volume (9.7 to 11.7 chips), 10 different doses for dose flexibility (8.0 to 13.2 chips), and short injection time below 5 seconds (8.5 to 11.1 chips).
UNASSIGNED: Arguments for the use of MTX pens as opposed to PFS predominantly refer to dosing/administration and ease of use. The new button-free MTX autoinjector combines a number of advantageous features identified by the international survey.
Subcutaneous injection of methotrexate (MTX) is an option to treat patients with specific inflammatory diseases. A new MTX autoinjector with button-free activation of the injection and no need to build a skin fold was developed to address some of the reasons for non-adherence. The importance of specific needs of users as well as the relevance of features of the new MTX autoinjector are unknown. Therefore, a structured questionnaire was distributed to physicians, nurses and patients in Germany, France, and the United Kingdom. Illustrations and information about features of the new MTX autoinjector were distributed to the participants. The results of the study show that arguments for the use of MTX pens as opposed to prefilled syringes predominantly affect the categories dosing/administration and ease of use followed by safety/side effects. In addition, the study identified four main advantageous features of the new MTX autoinjector, ie simplicity due to the 2-step button-free autoinjector mechanism, the small injection volume, 10 different doses for dose flexibility, and the short injection time below 5 seconds.
摘要：
■预充式注射器（PFS）和各种类型的笔可用于类风湿关节炎或中度至重度牛皮癣患者的皮下注射甲氨蝶呤（MTX）。开发了一种具有现代化的无按钮自动注射技术的新型MTX笔，作为按钮激活笔（metoject®/metex®PEN）的后继产品。为了评估用户的需求和新型MTX自动注射器功能的相关性，进行了一项国际在线调查。
■向医生分发了一份结构化问卷，德国的护士和病人，法国,和英国。参与者收到了有关新型MTX自动注射器功能的插图和信息。
■总共，189风湿病学家，111名皮肤科医生,90名护士,180名患者回答了问题。与PFS相比，更喜欢使用MTX笔的具体原因可能主要分为“给药/给药”和“易用性”类别。82％的医生对新型MTX自动注射器的第一印象是积极的，87%的护士，76%的患者，分别。新的MTX自动注射器的四个最重要的特征是2步自动注射器机制（接收总共100个芯片的平均14.1至18.1个芯片），小注入量（9.7至11.7芯片），10种不同剂量的剂量灵活性（8.0至13.2芯片），和短的注入时间低于5秒（8.5至11.1芯片）。
■使用MTX笔相对于PFS的论点主要是指给药/施用和易用性。新的无按钮MTX自动注射器结合了国际调查确定的许多优势特征。
皮下注射甲氨蝶呤（MTX）是治疗特定炎症性疾病患者的一种选择。开发了一种新的MTX自动注射器，无需按钮即可激活注射，无需构建皮肤褶皱，以解决不粘附的一些原因。用户的特定需求的重要性以及新的MTX自动注射器的功能的相关性是未知的。因此,一份结构化的问卷分发给医生，德国的护士和病人，法国,和英国。关于新的MTX自动注射器的特征的插图和信息被分发给参与者。研究结果表明，使用MTX笔而不是预充式注射器的论点主要影响给药/给药和易用性的类别，然后是安全/副作用。此外,该研究确定了新型MTX自动注射器的四个主要优势特征，即简单，由于2步骤无按钮自动注射器机制，小的注射体积，10种不同剂量的剂量灵活性，和短注射时间低于5秒。
■向医生分发了一份结构化问卷，德国的护士和病人，法国,和英国。参与者收到了有关新型MTX自动注射器功能的插图和信息。
■总共，189风湿病学家，111名皮肤科医生,90名护士,180名患者回答了问题。与PFS相比，更喜欢使用MTX笔的具体原因可能主要分为“给药/给药”和“易用性”类别。82％的医生对新型MTX自动注射器的第一印象是积极的，87%的护士，76%的患者，分别。新的MTX自动注射器的四个最重要的特征是2步自动注射器机制（接收总共100个芯片的平均14.1至18.1个芯片），小注入量（9.7至11.7芯片），10种不同剂量的剂量灵活性（8.0至13.2芯片），和短的注入时间低于5秒（8.5至11.1芯片）。
■使用MTX笔相对于PFS的论点主要是指给药/施用和易用性。新的无按钮MTX自动注射器结合了国际调查确定的许多优势特征。
皮下注射甲氨蝶呤（MTX）是治疗特定炎症性疾病患者的一种选择。开发了一种新的MTX自动注射器，无需按钮即可激活注射，无需构建皮肤褶皱，以解决不粘附的一些原因。用户的特定需求的重要性以及新的MTX自动注射器的功能的相关性是未知的。因此,一份结构化的问卷分发给医生，德国的护士和病人，法国,和英国。关于新的MTX自动注射器的特征的插图和信息被分发给参与者。研究结果表明，使用MTX笔而不是预充式注射器的论点主要影响给药/给药和易用性的类别，然后是安全/副作用。此外,该研究确定了新型MTX自动注射器的四个主要优势特征，即简单，由于2步骤无按钮自动注射器机制，小的注射体积，10种不同剂量的剂量灵活性，和短注射时间低于5秒。
